Deltex Medical Group plc (DTXMF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Deltex Medical Group plc (DTXMF) trades at $0.10 with AI Score 51/100 (Grade B). Deltex Medical Group plc specializes in oesophageal Doppler haemodynamic monitoring systems. Market cap: $180.58M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for DTXMF: DTXMF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DTXMF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
DTXMF: 3/6 perspectives are bullish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Deltex Medical Group plc (DTXMF) Healthcare & Pipeline Overview
Deltex Medical Group plc provides haemodynamic monitoring solutions, primarily through its TrueVue Doppler system, used in critical care and surgical settings. The company focuses on optimizing fluid management and blood flow in patients, operating within the competitive medical devices market, with a global presence in the UK, US, Spain, and Canada.
What Is the Investment Thesis for DTXMF?
Deltex Medical Group plc presents a focused investment opportunity within the haemodynamic monitoring sector. The company's TrueVue system addresses a critical need for precise fluid management in surgical and critical care settings. While the company's negative P/E ratio of -0.22 and profit margin of -72.2% indicate current challenges, the 63.3% gross margin suggests potential for profitability with increased sales and cost management. Growth catalysts include expanding adoption of TrueVue in the US market and potential partnerships with larger medical device companies. Key risks include competition from established players and the need for continued innovation to maintain market relevance. The company's beta of -2.55 suggests a low correlation with the overall market.
Based on FMP financials and quantitative analysis
DTXMF Key Highlights
- Market capitalization of $180.58M indicates the company's current valuation in the market.
- Negative P/E ratio of -0.22 reflects current unprofitability, suggesting potential for future earnings growth.
- Gross margin of 63.3% demonstrates the company's ability to generate revenue above the cost of goods sold.
- Beta of -2.55 indicates a negative correlation with the market, suggesting potential stability during market downturns.
- The company operates internationally, with a presence in the UK, US, Spain, and Canada, providing geographic diversification.
Who Are DTXMF's Competitors?
DTXMF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BLMHF Bloom Health Partners Inc. | $0.11 | +0.00% | $5.22M | 51 |
| DOCRF CloudMD Software & Services Inc. | $0.02 | -19.29% | $6.25M | 38 |
| FFLWF Fire & Flower Holdings Corp. | $0.12 | -44.37% | $5.42M | 41 |
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DTXMF's Key Strengths?
- Proprietary TrueVue oesophageal Doppler technology.
- Established presence in key markets (UK, US, Spain, Canada).
- Specialized product portfolio focused on haemodynamic monitoring.
- High gross margin (63.3%) indicates pricing power.
What Are DTXMF's Weaknesses?
- Negative profit margin (-72.2%) indicates profitability challenges.
- Small employee base (24) may limit scalability.
- Reliance on a single product line (TrueVue).
- OTC market listing may limit investor access.
What Could Drive DTXMF Stock Higher?
- Expansion of TrueVue adoption in US hospitals and surgical centers.
- Strategic partnerships with medical device distributors.
- Development of new haemodynamic monitoring technologies.
- Integration of TrueVue data with EHR systems.
What Are the Key Risks for DTXMF?
- Negative return on equity (-45.5%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Increased competition from established medical device companies.
- Technological obsolescence of TrueVue technology.
- Regulatory changes affecting medical device approvals.
- Economic downturns impacting hospital budgets.
- Negative profit margin and profitability challenges.
What Are the Growth Opportunities for DTXMF?
- Expansion in the US Market: Deltex Medical has a significant opportunity to expand its presence in the US market. The US medical device market is one of the largest in the world, with a growing demand for advanced haemodynamic monitoring technologies. By increasing its sales and marketing efforts in the US, Deltex Medical can capitalize on this demand and drive revenue growth. This expansion could be accelerated through strategic partnerships with US-based distributors or healthcare providers. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Deltex Medical can pursue strategic partnerships or acquisitions to expand its product portfolio and market reach. Collaborating with complementary medical device companies or acquiring smaller players with innovative technologies can enhance Deltex Medical's competitive position and accelerate growth. These partnerships could provide access to new markets, technologies, or distribution channels. Timeline: Ongoing.
- Product Innovation and Development: Continued investment in research and development is crucial for Deltex Medical to maintain its competitive edge. By developing new and improved haemodynamic monitoring technologies, the company can address unmet clinical needs and attract new customers. This includes exploring non-invasive monitoring solutions and integrating its technology with other medical devices. Timeline: Ongoing.
- Adoption in Emerging Markets: Deltex Medical can explore opportunities to expand its presence in emerging markets, where there is a growing demand for advanced medical technologies. These markets often have less stringent regulatory requirements and lower competitive intensity, providing a favorable environment for growth. However, it is important to carefully assess the market dynamics and regulatory landscape before entering these markets. Timeline: Ongoing.
- Integration with Electronic Health Records (EHR) Systems: Integrating Deltex Medical's haemodynamic monitoring data with EHR systems can enhance the value proposition for healthcare providers. This integration would allow clinicians to access real-time patient data and make more informed decisions. It would also streamline the workflow and reduce the risk of errors. Timeline: Ongoing.
What Opportunities Does DTXMF Have?
- Expansion in the US market.
- Strategic partnerships and acquisitions.
- Product innovation and development.
- Adoption in emerging markets.
What Threats Does DTXMF Face?
- Competition from established medical device companies.
- Technological obsolescence.
- Regulatory changes.
- Economic downturns affecting hospital budgets.
What Are DTXMF's Competitive Advantages?
- Proprietary oesophageal Doppler technology.
- Established brand reputation in haemodynamic monitoring.
- Specialized product portfolio focused on fluid management.
- Global distribution network.
What Does DTXMF Do?
Deltex Medical Group plc, established in 2000 and headquartered in Chichester, UK, develops, manufactures, and markets haemodynamic monitoring systems. Its flagship product, the TrueVue oesophageal Doppler monitoring (ODM) system, provides real-time blood flow and fluid status measurements. This technology assists clinicians in optimizing fluid management during surgery and in critical care settings. The company's product line includes esophageal Doppler Probes, Loops, High Definition Impedance Cardiography, PressureWave, and the Deltex Medical Esophageal Doppler Simulator. These products are utilized in a range of medical procedures, including major abdominal, laparoscopic, and spinal surgeries, cardiac, trauma, and transplant procedures, as well as in the management of conditions like sepsis and post-operative acute kidney injury. Deltex Medical distributes its products in the United Kingdom, the United States, Spain, and Canada, as well as internationally. Deltex Medical's focus on precision fluid management positions it within the broader medical devices market, catering to the needs of hospitals and surgical centers seeking to improve patient outcomes and reduce complications related to fluid imbalances.
What Products and Services Does DTXMF Offer?
- Manufactures oesophageal doppler haemodynamic monitoring systems.
- Markets TrueVue monitoring systems globally.
- Sells esophageal Doppler Probes for real-time blood flow measurement.
- Offers Loops for aortic blood flow and blood pressure monitoring.
- Provides High Definition Impedance Cardiography for non-invasive cardiac monitoring.
- Develops PressureWave algorithm for pulse pressure waveform analysis.
- Supplies Deltex Medical Esophageal Doppler Simulator for training.
How Does DTXMF Make Money?
- Direct sales of TrueVue haemodynamic monitoring systems.
- Recurring revenue from the sale of disposable esophageal Doppler Probes.
- Service and maintenance contracts for installed monitoring systems.
- Training and education programs for clinicians on the use of their products.
What Industry Does DTXMF Operate In?
Deltex Medical Group plc operates within the medical devices industry, specifically focusing on haemodynamic monitoring. The market is characterized by technological advancements and increasing demand for minimally invasive and precise monitoring solutions. Key trends include the growing adoption of advanced monitoring technologies in critical care and surgical settings, driven by the need to improve patient outcomes and reduce complications. The competitive landscape includes companies like ACRDF (Accuray Incorporated), BLMHF (Bellerophon Therapeutics Inc), DOCRF (Second Sight Medical Products Inc), FFLWF (Fluidigm Corporation), and PXMVF (Proximus NV), each offering various monitoring solutions. Deltex Medical differentiates itself through its unique oesophageal Doppler technology and focus on fluid management.
Who Are DTXMF's Key Customers?
- Hospitals and surgical centers.
- Critical care units.
- Anesthesiologists and surgeons.
- Medical professionals involved in fluid management during surgery and critical care.
How Deltex Medical Group plc Is Valued
Deltex Medical Group plc carries a market capitalization of $180.58M, placing it in the micro-cap category. Relative to its peer group, DTXMF's quantitative score of 51/100 is roughly in line with the peer average of 55/100.
Company Profile
Deltex Medical Group plc operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Chichester, GB. The company is led by CEO Natalie Emilia Wettler. DTXMF has traded publicly since 2009.
ROE -45%Key Financial Metrics
Return on equity for Deltex Medical Group plc stands at -45.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -21.6%, showing how much profit it generates from its asset base. A current ratio of 1.89 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 2/9Financial Health
Deltex Medical Group plc's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 8.47 places it in the safe zone, indicating low near-term bankruptcy risk.
DTXMF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that those closest to the business believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting innovative product developments that could enhance market position.
- Increased engagement from healthcare professionals on social platforms indicates growing recognition of Deltex's technology in patient monitoring.
- Recent partnerships in the healthcare sector are seen as a validation of Deltex's offerings, potentially expanding their market reach.
Bear Case
- Concerns about the overall economic environment may lead to reduced spending in healthcare, impacting Deltex's sales.
- Some community members express skepticism about the scalability of Deltex's technology, questioning its adoption in broader markets.
- Recent regulatory challenges have raised doubts about the speed of product approvals, which could delay growth plans.
- Market perception remains cautious, with some investors concerned about competition from larger players in the medical technology space.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
DTXMF Latest News
No recent news available for DTXMF.
DTXMF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DTXMF.
Price Targets
Wall Street price target analysis for DTXMF.
DTXMF MoonshotScore
What does this score mean?
The MoonshotScore rates DTXMF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Natalie Emilia Wettler
Managing Director
Natalie Emilia Wettler serves as the Managing Director of Deltex Medical Group plc. Information regarding her detailed career history and educational background is not available in the provided data. However, as Managing Director, she is responsible for overseeing the company's strategic direction and day-to-day operations.
Track Record: Due to limited information, specific achievements and milestones under Natalie Emilia Wettler's leadership cannot be detailed. However, as Managing Director, she is responsible for guiding the company's growth and profitability.
DTXMF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Deltex Medical Group plc may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and performance. Investing in companies on the OTC Other tier carries higher risks compared to those listed on major exchanges like the NYSE or NASDAQ due to the potential for less transparency and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to OTC Other tier status.
- Lower liquidity and potential for wider bid-ask spreads.
- Higher price volatility compared to major exchanges.
- Potential for less regulatory oversight and investor protection.
- Increased risk of fraud or manipulation.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal disputes involving the company.
- Understand the risks associated with investing in OTC stocks.
- Established operations in the UK, US, Spain, and Canada.
- Proprietary TrueVue technology.
- Presence in the haemodynamic monitoring market.
- Gross margin of 63.3% suggests a viable business model.
- Incorporated in 2000 indicates a history of operations.
What Investors Ask About Deltex Medical Group plc (DTXMF) — Healthcare
What does Deltex Medical Group plc do?
Deltex Medical Group plc specializes in haemodynamic monitoring solutions, primarily through its TrueVue system. This system utilizes oesophageal Doppler technology to measure a patient's central vascular blood flow and fluid status in real-time. The company's products are used in various surgical and critical care settings to optimize fluid management, improve patient outcomes, and reduce complications related to fluid imbalances. Deltex Medical operates in the global medical devices market, with a focus on precision fluid management.
What are the main risks for DTXMF?
Deltex Medical Group plc faces several risks, including competition from established medical device companies, the potential for technological obsolescence of its TrueVue technology, and regulatory changes affecting medical device approvals. The company's negative profit margin and profitability challenges also pose a significant risk. Additionally, economic downturns could impact hospital budgets and reduce demand for its products. As an OTC-listed company, DTXMF faces additional risks related to liquidity and transparency.
What are the key factors to evaluate for DTXMF?
Deltex Medical Group plc (DTXMF) holds an AI score of 51/100 (moderate). Not financial advice.
How frequently does DTXMF data refresh on this page?
DTXMF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven DTXMF's recent stock price performance?
Deltex Medical Group plc (DTXMF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary TrueVue oesophageal Doppler technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DTXMF overvalued or undervalued right now?
Valuing Deltex Medical Group plc (DTXMF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying DTXMF?
Before investing in Deltex Medical Group plc (DTXMF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding DTXMF to a portfolio?
Key strength of Deltex Medical Group plc (DTXMF): Proprietary TrueVue oesophageal Doppler technology. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- OTC market data may be limited or delayed.
- AI analysis pending for DTXMF.